Project Grant R01HL172903
Award Date
7/1/24
Completion Date
5/31/28
Dollars Obligated
$816K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $689,232 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Louisville Office of Research & Innovation to investigate a dual-targeting compound for preventing doxorubicin-induced cardiotoxicity in cancer patients. Specifically, the research aims to optimize the compound's protective effects against cardiotoxicity in tumor-free and tumor-bearing mice, determine its mechanisms of...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), totals $701,890.00 and is effective from January 15, 2025 through November 30, 2029. The award supports research to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The key objectives are to: 1) define how sunitinib translationally regulates the gene SND1, which is a potential novel regulator...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $726,408 to the University of Cincinnati to conduct research aimed at alleviating cardiovascular toxicity caused by cancer chemotherapy drugs. The key objectives are to: 1) Define the role of the transcription factor TFEB in endothelial cell dysfunction and the interaction between endothelial cells and cardiomyocytes caused by cancer...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University to conduct research focused on understanding the molecular mechanisms underlying cardiovascular toxicity caused by proteasome inhibitor cancer drugs, particularly carfilzomib. The key objectives are to leverage mouse models, human induced pluripotent stem cells, gene editing...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $324,440 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of North Carolina at Chapel Hill to assess the contribution of epigenetics to cardiovascular risk in African American women. The project aims to identify epigenetic biomarkers of cardiovascular disease and its environmental determinants, and evaluate if these biomarkers can improve cardiovascular disease risk prediction...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $700,398 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant aims to integrate spatial transcriptomics, genetics, and histomorphology to provide insights into the molecular and cellular mechanisms underlying atherosclerotic cardiovascular disease (CVD) risk. Specifically, the project will:
Apply...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $198,936 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to New York University School of Medicine (NYU) for the purpose of studying the impact of restrictive drug coverage policies on heart failure care. The project aims to quantify the effects of cost-sharing requirements and prior authorization policies on provider prescribing practices, patient medication adherence, and clinical outcomes for guideline-recommended...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $782,672 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Brigham & Women's Hospital. The grant funding will support research to identify previously unrecognized genetic causes of congenital heart disease (CHD). The project aims to assess the contributions of non-coding and rare coding variants to unexplained CHD cases, using a combination of cell-based functional assays, single-nucleus RNA...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $874,792 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vanderbilt University Medical Center (VUMC). The 4-year grant, effective July 15, 2024 through June 30, 2028, will fund research to:
Identify new genetic variants associated with residual atherosclerotic cardiovascular disease (ASCVD) risk in patients on treatment to lower LDL-cholesterol and blood pressure. This will involve conducting...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,413,971 Project Grant to the University of Pittsburgh to study the role of the MDM2-HIF signaling axis in regulating pathological left ventricular remodeling. The research aims to define how this signaling pathway impacts myocardial microvasculature, metabolism, and remodeling in both genetic and pressure overload models of left ventricular hypertrophy. The...